联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03933 联邦制药

休市中 09-11 16:08:55

7.940

-0.195

-2.40%

最高8.105	最低7.930	成交量1,077万
今开8.080	昨收8.135	日振幅2.15%
总市值156.42亿	流通市值156.42亿	总股本19.70亿
成交额8,612万	换手率0.55%	流通股本19.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03933","market":"HK","secType":"STK","nameCN":"联邦制药","latestPrice":7.94,"timestamp":1789114135006,"preClose":8.135,"halted":0,"volume":10770024,"delay":0,"changeRate":-0.0239704978488014,"floatShares":1970000000,"shares":1970000000,"eps":1.2941194600021964,"marketStatus":"休市中","change":-0.195,"latestTime":"09-11 16:08:55","open":8.08,"high":8.105,"low":7.93,"amount":86123002,"amplitude":0.021512,"askPrice":7.955,"askSize":2000,"bidPrice":7.94,"bidSize":50000,"shortable":3,"etf":0,"ttmEps":0.32124922067429124,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":7,"adr":0,"listingDate":1181836800000,"exchange":"SEHK","adjPreClose":8.135,"dividendRate":0.038195,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":2.364512630397556,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03933","defaultTab":"news","newsList":[{"id":"2666831355","title":"瑞银：中国制药股上半年业绩好坏参半 首选先声药业(02096)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666831355","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666831355?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:43","pubTimestamp":1788939780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，中国制药股上半年业绩好坏参半，在九家评级的制药公司中，有五家业绩好过市场预期，分别为翰森制药、先声药业、中国生物制药、石药集团及科伦药业，联邦制药表现大致符合预期，而三生制药及华东医药表现则逊预期，全数给予“买入”评级。瑞银列先声药业行业首选股，指出先声药业是唯一上调2026年指引的公司，经调整纯利增长目标由30%上调至45%，收入增长维持30%，给予目标价16.6港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YS42.EUR","IE00B3M56506.USD","BK1593","IE00BZ08YR35.GBP","BK1589","01530","BK1515","BK1521","02096","BK1583","BK1191","03933","BK1574","01477","03692","HK0000165453.HKD","01177","BK1161","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665234873","title":"【券商聚焦】华泰维持联邦制药（03933）买入评级 看好代谢管线及动保业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2665234873","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665234873?lang=zh_cn&edition=full","pubTime":"2026-09-08 16:03","pubTimestamp":1788854597,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰发布研报指，联邦制药 1H26实现收入61.7亿元，归母净利润3.48亿元，符合此前盈利预告。收入下滑主因授权费用同比减少及中间体业务销售下滑；利润下滑幅度更大主因6APA价格虽环比提升但仍低于1H25同期水平。展望26年，华泰看好公司维持6-8亿元利润预期，维持“买入”评级，目标价12.61港元。华泰看好UBT251在26年为公司贡献2500万美元里程碑，27年贡献7000万至1.3亿美元里程碑收入。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991036","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191775486","title":"联邦制药(03933)长效三靶点激动剂UBT251在华III期临床完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1191775486","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191775486?lang=zh_cn&edition=full","pubTime":"2026-09-07 20:46","pubTimestamp":1788785175,"startTime":"0","endTime":"0","summary":"2026年9月7日，联邦制药国际控股有限公司公告称，其全资附属公司联邦生物科技有限公司自主研发的1类创新药UBT251注射液，已在中国针对2型糖尿病的III期临床试验完成首例受试者给药。此次III期项目分为“UNIGUIDE-1”和“UNIGUIDE-2”两项独立研究。据公告，联邦制药是中国首家、全球第二家以化学合成多肽法制备长效GLP-1R/GIPR/GCGR三靶点激动剂并获批临床的企业。此前，联邦生物科技及联邦制药已于2025年3月与Novo Nordisk A/S签署UBT251的独家许可协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665314872","title":"联邦制药(03933)：UBT251注射液完成中国2型糖尿病III期临床研究首例试验参与者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2665314872","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665314872?lang=zh_cn&edition=full","pubTime":"2026-09-07 20:45","pubTimestamp":1788785154,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 发布公告，公司全资附属公司联邦生物科技有限公司自主研发的 1 类创新药 UBT251 注射液已完成中国 2 型糖尿病 III 期临床研究首例试验参与者给药。本研究将分别进行“UNIGUIDE-1”及“UNIGUIDE-2”两项研究。UNIGUIDE-1 采用随机、双盲、平行、安慰剂对照的试验设计，计划纳入 360 例成人 2 型糖尿病试验参与者，旨在评估 UBT251 注射液在单纯饮食运动干预后血糖控制不佳的 2 型糖尿病试验参与者中的有效性和安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03933","IE00B3M56506.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665318052","title":"瑞银：下调联邦制药(03933)目标价至12.8港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2665318052","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665318052?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:04","pubTimestamp":1788771882,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，联邦制药上半年收入同比下降18%至62亿元人民币，仍高于该行及市场预期，受动物保健及授权收入支持;纯利同比下降82%，大致符合初步业绩及该行预期。该行将联邦制药目标价由15港元下调至12.8港元，维持“买入”评级。研发开支同比下降12%至4.39亿元人民币，销售及行政开支则同比增长1.7%至11亿元人民币。人用制剂产品则轻微下降2%至19亿元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03933","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665394525","title":"大行评级丨瑞银：下调联邦制药目标价至12.8港元，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2665394525","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665394525?lang=zh_cn&edition=full","pubTime":"2026-09-07 14:17","pubTimestamp":1788761822,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1191","03933","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398249","title":"【券商聚焦】中信建投：上半年收入与利润双增，医药行业步入新发展周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398249","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398249?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:04","pubTimestamp":1788743053,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业整体收入与扣非净利润实现双增长，创新药、CXO、制药装备及科学试剂等板块积极复苏，行业步入新发展周期。创新药收入+58.68%，扭亏为盈，出海总金额超900亿美元，全年有望超越2025年水平，国际化持续兑现；CXO收入+25.2%，扣非净利润+66.5%，订单旺盛，上行周期确立。随着集采出清、创新放量、出海落地及上游国产化提升，行业有望开启高质量发展周期，龙头将持续受益。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990791","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU0417516902.SGD","LU2778985437.USD","LU2328871848.SGD","KURE","01099","LU2399975544.HKD","LU1720050803.USD","BK1207","IE00B3M56506.USD","02268","LU1115378108.SGD","LU0588546209.SGD","09688","01789","BK1588","06821","LU0348827113.USD","LU0348825331.USD","BK1593","IE00BPRC5H50.USD","LU1969619763.USD","BK1585","01530","BK1515","09926","KCE","02228","LU0228659784.USD","LU0828237510.HKD","SG9999004311.SGD","LU2476274308.USD","BK1583","02367","IE00B5MMRT66.SGD","BK1191","03933","BK1574","601066","BK1197","LU2476274720.SGD","06160","02196","HK0000165453.HKD","LU0640798160.USD","BK1141","LU1770034418.SGD","BK1100","BK1161","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664336457","title":"联邦制药(03933)：UBT251注射液完成中国超重/肥胖III期临床研究首例试验参与者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2664336457","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664336457?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:55","pubTimestamp":1788519354,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药(03933)发布公告，公司全资附属公司联邦生物科技(珠海横琴)有限公司(联邦生物科技)自主研发的1类创新药UBT251注射液已完成中国超重/ 肥胖III期临床研究首例试验参与者给药。本研究采用随机、双盲、平行、安慰剂对照的试验设计，计划纳入600例肥胖(BMI≥28.0 kg/m2)或伴有至少一种体重相关合并症的超重(24.0 kg/m2≤BMI<28.0 kg/m2)试验参与者，旨在评估UBT251注射液在超重/肥胖试验参与者中有效性和安全性。本研究的主要评价终点为给药52周试验参与者体重较基线变化百分比及体重较基线降低≥5%的试验参与者比例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B3M56506.USD","03933","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112486081","title":"联邦制药（03933）UBT251注射液完成中国超重/肥胖Ⅲ期临床首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1112486081","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112486081?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:51","pubTimestamp":1788519104,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司9月4日自愿公告，其全资附属公司联邦生物科技有限公司自主研发的1类创新药UBT251注射液已在中国超重/肥胖Ⅲ期临床研究中完成首例试验参与者给药。主要评估终点为给药52周后体重较基线的百分比变化及体重较基线降低≥5%的试验参与者比例。公告同时披露，2025年3月，联邦生物科技及公司已与Novo Nordisk A/S签订UBT251的独家许可协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664872145","title":"联邦制药：上半财年资本承担10.44亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872145","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664872145?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:43","pubTimestamp":1788439405,"startTime":"0","endTime":"0","summary":"南财智讯9月3日电，联邦制药（03933.HK）公告，截至二零二六年六月三十日止六个月，本集团因已订约购置物业、厂房及设备而产生但未于简明综合财务报表内拨备之资本开支承担为人民币10.44亿元（二零二五年十二月三十一日：人民币13.19亿元）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864277544.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864277544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","03933","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119446896","title":"联邦制药2026年中期业绩：资本开支承诺降至人民币10.44亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119446896","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119446896?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:36","pubTimestamp":1788439001,"startTime":"0","endTime":"0","summary":"本季度信息\n联邦制药于2026年8月31日发布截至2026年6月30日止六个月的中期业绩公告并作出澄清。根据最新说明，财务报表附注14中“于2026年6月30日的资本承诺”修订为人民币1,044,131,000元，较2025年12月31日披露的人民币1,319,378,000元有所减少。除该项修订外，董事会确认公告的其他信息保持不变。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"联邦制药2026年中期业绩：资本开支承诺降至人民币10.44亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131906804","title":"联邦制药8月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1131906804","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131906804?lang=zh_cn&edition=full","pubTime":"2026-09-03 12:12","pubTimestamp":1788408733,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司于2026年9月3日发布的月报显示，截至2026年8月31日，公司在当月并无任何新的股份发行或回购活动，股本结构维持稳定。联邦制药的月报披露，公司法定/注册股本规格为3,800,000,000股，每股面值为0.01港元，总面值合计38,000,000港元，与上月保持不变。报告期已发行股份总数为1,970,276,508股，相较上月并无任何变动，公司确认已维持适用的公众持股量要求。公告显示，报告期内，未有股份期权或股权激励计划变动，也无购回或注销股份行为。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664828446","title":"中金：降联邦制药(03933.HK)目标价至12港元 上半年经调整利润符预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2664828446","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664828446?lang=zh_cn&edition=full","pubTime":"2026-09-03 09:57","pubTimestamp":1788400651,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","IE00B3M56506.USD","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182841678","title":"联邦制药2026年上半年营收61.66亿元，净利润3.48亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182841678","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182841678?lang=zh_cn&edition=full","pubTime":"2026-08-31 23:11","pubTimestamp":1788189083,"startTime":"0","endTime":"0","summary":"截至2026年6月30日止6个月，联邦制药实现收入61.66亿元，同比下降18.0%。报告期内，集团毛利为21.19亿元，同比减少46.0%，对应毛利率约34.4%，对比上年同期有明显下降。未计利息、税项、折旧及摊销前利润约9.21亿元，同比下降66.5%。管理层称主要受到产品结构调整以及市场环境变化等因素影响。报告期内，销售及分销开支为6.78亿元，同比微降0.6%；行政开支为4.58亿元，同比上升5.2%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"联邦制药2026年上半年营收61.66亿元，净利润3.48亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663973004","title":"联邦制药：上半财年净利润同比减少81.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663973004","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663973004?lang=zh_cn&edition=full","pubTime":"2026-08-31 23:03","pubTimestamp":1788188626,"startTime":"0","endTime":"0","summary":"南财智讯8月31日电，联邦制药（03933.HK）公告，截至二零二六年六月三十日止中期，公司总收益为61.66亿元人民币，同比减少18.0%；毛利为21.19亿元人民币，同比减少46.0%；本公司拥有人应占年内利润为3.48亿元人民币，同比减少81.6%；每股基本盈利为0.18元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860443980.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860443980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138571067","title":"UNITED LAB2025年度补充公告聚焦公司治理与持续关连交易合规","url":"https://stock-news.laohu8.com/highlight/detail?id=1138571067","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138571067?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:45","pubTimestamp":1787831138,"startTime":"0","endTime":"0","summary":"UNITED LAB就截至2025年12月31日止年度发布补充公告，重点说明公司在企业治理及持续关连交易合规方面的最新信息。公告显示，公司在董事会的监督下严格遵循相关上市规则，针对与业务合作伙伴之间的持续关连交易建立了审核安排，并由公司独立非执行董事对交易的公平合理性及日常业务性进行审阅和确认。所涉交易基于2024年6月3日签署的相关《主销售协议》，其条款及年度上限均已获得独立非执行董事核实并通过审计，以确保符合上市规则要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"UNITED LAB2025年度补充公告聚焦公司治理与持续关连交易合规","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197349018","title":"联邦制药2025年度补充公告强调合规治理与持续关连交易审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1197349018","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197349018?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:48","pubTimestamp":1787827712,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司在其2025年度报告的补充公告中，详细阐述了公司治理结构和持续关连交易的合规审核情况。公告显示，公司就与牧原食品的持续关连交易已依据香港联合交易所有限公司证券上市规则第14A章进行备案及信息披露，独立核数师对相关交易文件进行审阅并未提出保留意见。在公司治理方面，本集团强调合规与审查程序，通过董事会层面的审批机制对持续关连交易进行综合性管控。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"联邦制药2025年度补充公告强调合规治理与持续关连交易审查","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660442700","title":"联邦制药预计上半年净溢利同比降至约3.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660442700","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660442700?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:42","pubTimestamp":1787136120,"startTime":"0","endTime":"0","summary":"8月19日，联邦制药（03933）发布公告，公司预计2026年上半年净溢利约为3.4亿元，而去年同期则为18.93亿元。公告提到，净溢利减少受中间体产品及原料药分部的产品市场价格下行及需求调整的影响。此外，2026年上半年来自诺和诺德（NVO.N）许可费收入约1.01亿元，而去年同期则约为14.33亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608193846427450.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608193846427450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03933","IE00B3M56506.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133868975","title":"联邦制药（03933）发出盈利警告：上半年净利预计约3.4亿元，同比大幅下降","url":"https://stock-news.laohu8.com/highlight/detail?id=1133868975","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133868975?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:35","pubTimestamp":1787135744,"startTime":"0","endTime":"0","summary":"2026年8月19日，联邦制药国际控股有限公司发布盈利警告。根据集团截至2026年6月30日止六个月按香港财务报告准则编制的未经审计综合管理账目，预计期内净利润约为3.4亿元人民币，而上年同期净利润约为18.93亿元人民币。同时，来自Novo Nordisk A/S的许可费收入由2025年上半年的约14.33亿元人民币下降至2026年上半年的约1.01亿元人民币。联邦制药计划在即将发布的2026年中期业绩公告及中期报告中披露详尽业绩。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660440874","title":"联邦制药(03933.HK)发盈警 预计中期净溢利约3.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660440874","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660440874?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:28","pubTimestamp":1787135317,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","IE00B3M56506.USD","03933"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tul.com.cn","stockEarnings":[{"period":"1week","weight":-0.0497},{"period":"1month","weight":-0.1202},{"period":"3month","weight":-0.0649},{"period":"6month","weight":-0.2594},{"period":"1year","weight":-0.505},{"period":"ytd","weight":-0.2933}],"compareEarnings":[{"period":"1week","weight":-0.033},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0035},{"period":"6month","weight":-0.0259},{"period":"1year","weight":-0.0491},{"period":"ytd","weight":-0.0322}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"联邦制药国际控股有限公司是一家投资控股公司，主要从事销售中间体产品、原料药及制剂产品业务。该公司通过三个业务部门运营业务。中间体部从事销售中间体产品业务。原料药部从事销售原料药业务。制剂产品部从事销售抗生素制剂产品、非抗生素制剂产品及空心胶囊业务。该公司通过其子公司还从事制造及销售有机化肥业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.368421,"avgChangeRate":-0.033072},{"month":2,"riseRate":0.736842,"avgChangeRate":0.075941},{"month":3,"riseRate":0.631579,"avgChangeRate":0.024557},{"month":4,"riseRate":0.578947,"avgChangeRate":0.075619},{"month":5,"riseRate":0.631579,"avgChangeRate":0.035298},{"month":6,"riseRate":0.263158,"avgChangeRate":-0.013942},{"month":7,"riseRate":0.55,"avgChangeRate":0.015909},{"month":8,"riseRate":0.45,"avgChangeRate":0.020395},{"month":9,"riseRate":0.4,"avgChangeRate":-0.008477},{"month":10,"riseRate":0.631579,"avgChangeRate":-0.000878},{"month":11,"riseRate":0.473684,"avgChangeRate":-0.023224},{"month":12,"riseRate":0.421053,"avgChangeRate":0.011203}],"exchange":"SEHK","name":"联邦制药","nameEN":"UNITED LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"联邦制药,03933,联邦制药股票,联邦制药股票老虎,联邦制药股票老虎国际,联邦制药行情,联邦制药股票行情,联邦制药股价,联邦制药股市,联邦制药股票价格,联邦制药股票交易,联邦制药股票购买,联邦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}